EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis

Soyoung Park, Tae-Gyun Woo, So-Mi Kang, Bae-Hoon Kim iD, Bum-Joon Park iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27062867 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Soyoung Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Rare Genetic Disease, PRG S&Tech Co., Ltd., Busan 46274, Republic of Korea. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Skin Neoplasms, Neurilemmoma, Neurofibromatoses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University, 2-Year Research Grant from Pusan National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 (NF1) and NF2-related schwannomatosis (NF2-SWN) are major genetic tumor predisposition syndromes characterized by progressive, often debilitating neoplasms of the peripheral and central nervous systems. Over the past five years, substantial advances in molecular genetics, signaling biology, and targeted therapeutic development have reshaped diagnostic and management paradigms for both disorders. This Perspective synthesizes recent developments, including gene-based reclassification, emergence of MEK inhibitor therapy in NF1, renewed evaluation of bevacizumab and kinase-pathway inhibitor brigatinib, the discovery of a novel TβR1-RKIP pathogenic axis, and a brain-penetrant HDAC inhibitor in NF2-SWN. These insights highlight a shift toward precision-medicine strategies and mechanistically driven therapies poised to redefine future clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Skin NeoplasmsNeurilemmomaNeurofibromatosesNeurofibromatosis 2HumansAnimals

Stichwörter der Autor:innen

AR-42NF2-SWNPRG-N-01bevacizumabbrigatinibneurofibromatosis type 1selumetinib

Autor:innen und Institutionen

  • Institute of Rare Genetic Disease, PRG S&Tech Co., Ltd., Busan 46274, Republic of Korea.
  • Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea.
  • Institute of Systems Biology, Pusan National University, Busan 46241, Republic of Korea.

ORCID-Profile: Bae-Hoon Kim, Bum-Joon Park

Förderung

  • Pusan National University
  • 2-Year Research Grant from Pusan National University

Zitieren

APA

Park, S., Woo, T. G., Kang, S. M., Kim, B. H., & Park, B. J. (2026). Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062867

Vancouver

Park S, Woo TG, Kang SM, Kim BH, Park BJ. Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062867

BibTeX
@article{Park2026,
  author = {Park, Soyoung and Woo, Tae-Gyun and Kang, So-Mi and Kim, Bae-Hoon and Park, Bum-Joon},
  title = {Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27062867}
}
Kostenlos starten →